Nasdaq:US$13.89 (+0.03) | HKEX:HK$22.45 (+0.50) | AIM:£2.07 (+0.01)
搜索
搜索结果
上一篇文章   |   下一篇文章
公告及新闻稿, 肿瘤学 / 免疫学 | 2009-02-17

Chi-Med Announces Completion of Patient Enrolment in its US Phase II Crohn’s Disease Clinical Trial of HMPL-004, its Lead Anti-Inflammatory Drug Candidate